Onivyde Cost in the United States
The price of Onivyde in the United States varies based on the specific formulation and dosage. A 30-day supply of Onivyde, a liposomal irinotecan injection used to treat pancreatic cancer, typically costs around \$7,000 to \$8,000 [1]. The exact cost can fluctuate due to factors such as pharmacy pricing, insurance coverage, and patient assistance programs.
What is Onivyde used for?
Onivyde is indicated for the treatment of metastatic adenocarcinoma of the pancreas in combination with fluorouracil and leucovorin in patients who have been previously treated with gemcitabine-based chemotherapy [1]. It is a prodrug of irinotecan, a topoisomerase I inhibitor, and its liposomal encapsulation is designed to improve drug delivery and potentially reduce toxicity [2].
How does insurance affect Onivyde's cost?
Insurance coverage significantly impacts the out-of-pocket expense for Onivyde. Many insurance plans provide coverage for Onivyde, but patients may still be responsible for co-pays, deductibles, and co-insurance. The specific costs will depend on the terms of the individual insurance plan.
Are there patient assistance programs for Onivyde?
Yes, there are patient assistance programs available that can help reduce the financial burden of Onivyde treatment. These programs, often run by pharmaceutical manufacturers or non-profit organizations, may offer financial assistance to eligible patients who meet certain income and insurance criteria. For example, the manufacturer of Onivyde may offer a co-pay assistance program [3]. Information on these programs can typically be found on the drug manufacturer's website or through healthcare providers.
When does the patent for Onivyde expire?
Patent expiration dates are crucial for understanding the potential for generic competition and subsequent price reductions. Information regarding Onivyde's patent status and expiration dates can be found on specialized resources like DrugPatentWatch.com [4]. Generally, once a patent expires, generic versions of the drug can be developed and marketed, which often leads to a decrease in the overall price of the medication.
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is part of a broader landscape of treatments for pancreatic cancer, which often involve chemotherapy regimens. It is typically used in patients who have progressed on or after first-line gemcitabine-based chemotherapy. Other treatment options for pancreatic cancer may include other chemotherapy drugs, targeted therapies, immunotherapy, radiation therapy, and surgery, depending on the stage and type of cancer [1, 2]. The choice of treatment is individualized and based on a patient's specific condition and medical history.
What are the side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and fever. More serious side effects can also occur, such as severe diarrhea, neutropenia, and febrile neutropenia. Patients should discuss potential side effects and management strategies with their healthcare provider [1].
---
Sources:
1. https://www.drugpatentwatch.com/drug/onivyde/
2. https://www.drugpatentwatch.com/drug/onivyde/
3. https://www.drugpatentwatch.com/drug/onivyde/
4. https://www.drugpatentwatch.com/drug/onivyde/